Oral antiretroviral drugs as public health tools for HIV prevention: Global implications for adherence, drug resistance, and the success of HIV treatment programs

Journal of Infectious Diseases

Volumn 207, Issue SUPPL.2, 2013, Pages

  Gupta, Ravindra K ^a   Wainberg, Mark A ^b   Brun Vezinet, Francoise ^c,d   Gatell, Jose M ^e   Albert, Jan ^f,g   Sönnerborg, Anders ^f,h   Nachega, Jean B ^i,j,k  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b MCGILL UNIVERSITY   (Canada)

^c BICHAT HOSPITAL   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e UNIVERSITY OF BARCELONA   (Spain)

^f KAROLINSKA INSTITUTE   (Sweden)

^g The Institute of Environmental Medecine   (Sweden)

^h KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

ⁱ UNIVERSITY OF STELLENBOSCH   (South Africa)

^j UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^k JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

more..

Author keywords

adherence; antiretroviral drug resistance; PrEP; TasP

Indexed keywords

ABACAVIR; ABACAVIR PLUS STAVUDINE PLUS TENOFOVIR; ANTIRETROVIRUS AGENT; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; LAMIVUDINE PLUS STAVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; UNCLASSIFIED DRUG;

ARTICLE; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG RESISTANCE; EPIDEMIC; HEALTH PROGRAM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; PATIENT COMPLIANCE; PRIORITY JOURNAL; PUBLIC HEALTH; TREATMENT FAILURE;

ADHERENCE; ANTIRETROVIRAL DRUG RESISTANCE; PREP; TASP;

ADENINE; ADMINISTRATION, ORAL; ANTI-HIV AGENTS; COUNSELING; DEOXYCYTIDINE; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV-1; HUMANS; ORGANOPHOSPHONATES; PATIENT COMPLIANCE; PUBLIC HEALTH;

EID: 84878306536     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jit108     Document Type: Article

References (38)

1. Joint United Nations Programme on HIV/AIDS (UNAIDS). Global report: UNAIDS report on the global AIDS epidemic, 2011. Geneva: UNAIDS, 2012.
2. World Health Organization (WHO). Antiretroviral drugs for treating pregnant women and preventing HIV infections in infants: recommendations for a public health approach: 2010 version. Geneva: WHO, 2010.
3. Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010; 329:1168-74.
4. Mills E, Cooper C, Anema A, Guyatt G. Male circumcision for the prevention of heterosexually acquired HIV infection: a meta-analysis of randomized trials involving 11, 050 men. HIV Med 2008; 9:332-5.
5. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011; 365:493-505.
6. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylax-is for HIV prevention in men who have sex with men. N Engl J Med 2010; 363:2587-99.
7. Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med 2012; 367:399-410.
8. Thigpen MC, Kebaabetswe PM, Paxton LA, et al. Antiretroviral preex-posure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med 2012; 367:423-34.
9. De Cock KM, Fowler MG, Mercier E, et al. Prevention of mother-to-child HIV transmission in resource-poor countries: translating research into policy and practice. JAMA 2000; 283:1175-82.
10. Townsend CL, Cortina-Borja M, Peckham CS, de Ruiter A, Lyall H, Tookey PA. Low rates of mother-to-child transmission of HIV following effective pregnancy interventions in the United Kingdom and Ireland, 2000-2006. AIDS 2008; 22:973-81.
11. Perelson AS, Essunger P, Cao Y, et al. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 1997; 387:188-91.
12. Nachega JB, Uthman OA, Anderson J, et al. Adherence to antiretroviral therapy during and after pregnancy in low-income, middle-income, and high-income countries: a systematic review and meta-analysis. AIDS 2012; 26:2039-52.
13. Hamers RL, Schuurman R, Sigaloff KC, et al. Effect of pretreatment HIV-1 drug resistance on immunological, virological, and drug-resistance outcomes of first-line antiretroviral treatment in sub-Saharan Africa: a multicentre cohort study. Lancet Infect Dis 2012; 12:307-17.
14. Hamers RL, Sigaloff KC, Wensing AM, et al. Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. Clin Infect Dis 2012; 54:1660-9.
15. Wittkop L, Gunthard HF, de Wolf F, et al. Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infect Dis 2011; 11:363-71.
16. Montaner JS, Lima VD, Barrios R, et al. Association of highly active an-tiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study. Lancet 2010; 376:532-9.
17. Tanser F, Bärnighausen T, Grapsa E, et al. Effect of ART coverage on rate of new HIV Infections in a hyperendemic, rural population: South Africa. In: 19th Conference on Retroviruses and Opportunistic Infections, Seattle, Washington, 2012.
18. Granich R, Kahn JG, Bennett R, et al. Expanding ART for treatment and prevention of HIV in South Africa: estimated cost and cost-effectiveness 2011-2050. PLoS One 2012; 7:e30216.
19. Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet 2009; 373:48-57.
20. Hontelez JA, de Vlas SJ, Tanser F, et al. The impact of the new WHO antiretroviral treatment guidelines on HIV epidemic dynamics and cost in South Africa. PLoS One 2011; 6:e21919.
21. Meyer-Rath G, Over M. HIV treatment as prevention: modelling the cost of antiretroviral treatment-state of the art and future directions. PLoS Med 2012; 9:e1001247.
22. Wagner B, Blower S. Costs of eliminating HIV in South Africa have been underestimated. Lancet 2010; 376:953-4.
23. Mills EJ, Nachega JB, Buchan I, et al. Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis. JAMA 2006; 296:679-90.
24. Hall HI, Hughes D, Dean HD, Mermin JH, Fenton KA. HIV infection-United States, 2005 and 2008. MMWR Surveill Summ 2011; 60(Suppl): 87-9.
25. Thompson MA, Mugavero MJ, Amico KR, et al. Guidelines for improving entry into and retention in care and antiretroviral adherence for persons with HIV: evidence-based recommendations from an International Association of Physicians in AIDS Care panel. Ann Intern Med 2012; 156:817-33, W-284, W-285, W-286, W-287, W-288, W-289, W-290, W-291, W-292, W-293, W-294.
26. Kaplan R, Orrell C, Zwane E, Bekker LG, Wood R. Loss to follow-up and mortality among pregnant women referred to a community clinic for antiretroviral treatment. AIDS 2008; 22:1679-81.
27. Fogel J, Li Q, Taha TE, et al. Initiation of antiretroviral treatment in women after delivery can induce multiclass drug resistance in breastfeeding HIV-infected infants. Clin Infect Dis 2011; 52:1069-76.
28. Zeh C, Weidle PJ, Nafisa L, et al. HIV-1 drug resistance emergence among breastfeeding infants born to HIV-infected mothers during a single-arm trial of triple-antiretroviral prophylaxis for prevention of mother-to-child transmission: a secondary analysis. PLoS Med 2011; 8: e1000430.
29. Doualla-Bell F, Avalos A, Brenner B, et al. High prevalence of the K65R mutation in human immunodeficiency virus type 1 subtype C isolates from infected patients in Botswana treated with didanosine-based regimens. Antimicrob Agents Chemother 2006; 50:4182-5.
30. Hosseinipour MC, van Oosterhout JJ, Weigel R, et al. The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. AIDS 2009; 23:1127-34.
31. Sunpath H, Wu B, Gordon M, et al. High rate of K65R for antiretroviral therapy-naive patients with subtype C HIV infection failing a tenofo-vir-containing first-line regimen. AIDS 2012; 26:1679-84.
32. Wainberg MA, Zaharatos GJ, Brenner BG Development of antiretroviral drug resistance. N Engl J Med 2011; 365:637-46.
33. National Institute of Allergy and Infectious Diseases, National Institutes of Health. NIH modifies 'VOICE' HIV prevention study in women [news release]. 28 September 2011. http://www.nih.gov/news/health/sep2011/niaid-28. htm. Accessed 19 March 2013.
34. Van Damme L, Corneli A, Ahmed K, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med 2012; 367: 411-22.
35. Haberer J, Baeten J, Celum C, et al. Near perfect early adherence to antiretroviral PrEP against HIV infection among HIV serodiscordant couples as determined by multiple measures: preliminary data from the Partners PrEP study. In: 18th Conference on Retroviruses and Opportunistic Infections, Boston, Massachusetts, 2011.
36. Ware NC, Wyatt MA, Haberer JE, et al. What's love got to do with it? Explaining adherence to oral antiretroviral preexposure prophylaxis for HIV-serodiscordant couples. J Acquir Immune Defic Syndr 2012; 59:463-8.
37. van der Straten A, Van Damme L, Haberer JE, Bangsberg DR. Unraveling the divergent results of preexposure prophylaxis trials for HIV prevention. AIDS 2012; 26:F13-9.
38. World Health Organization (WHO). Global HIV/AIDS response: epidemic update and health sector progress towards universal access: progress report 2011. Geneva: WHO, 2011.